Business Segments Beam Therapeutics Inc.
Equities
BEAM
US07373V1052
Biotechnology & Medical Research
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.34 USD | +1.33% |
|
+5.66% | -5.74% |
Sales 2024 by Business Segment
Sales 2024 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||
Biotechnology (Startups) | 24K | 51.84M | 60.92M | 378M | 63.52M | |||
Total Assets | 452M | 1.47B | 1.34B | 1.46B | 1.1B | |||
Interest Expense | - | -9K | - | - | - | |||
Income Tax Expense | - | - | - | 1.37M | 39K | |||
CAPEX | -16.36M | -46.81M | -48.95M | -33.73M | -8.95M | |||
EBT | -195M | -371M | -260M | -131M | -377M | |||
D&A | 4.74M | 7.45M | 14.15M | 20.01M | 21.92M | |||
Operating Income | -133M | -392M | -338M | -176M | -416M | |||
Net Income | -195M | -371M | -260M | -133M | -377M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
United States | 24K | 51.84M | 60.92M | 378M | 63.52M | |||
Total Assets | 452M | 1.47B | 1.34B | 1.46B | 1.1B | |||
Interest Expense | - | -9K | - | - | - | |||
Income Tax Expense | - | - | - | 1.37M | 39K | |||
D&A | 4.74M | 7.45M | 14.15M | 20.01M | 21.92M | |||
CAPEX | -16.36M | -46.81M | -48.95M | -33.73M | -8.95M | |||
Net Income | -195M | -371M | -260M | -133M | -377M | |||
EBT | -195M | -371M | -260M | -131M | -377M | |||
Operating Income | -133M | -392M | -338M | -176M | -416M |
- Stock Market
- Equities
- BEAM Stock
- Financials Beam Therapeutics Inc.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition